Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.
Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.
Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.
Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.
Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.
Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.
NAVIGATION
|
26
Feb |
LifeScan Canada Recalls 3 Lots Of OneTouch(R) SureStep(R) Test StripsCategory: Diabetes | Leave a Comment |
LifeScan Canada Ltd., is conducting a voluntary recall in Canada of 3 lots of OneTouch® SureStep® Test Strips used by people with diabetes to measure their blood glucose levels at home. The test strips are being recalled because they may provide falsely low glucose results when the glucose level is higher than 22.2 mmol/L…
|
26
Feb |
LifeScan Recalls Specific Lots Of Consumer And Professional OneTouch(R) SureStep(R) Test Strips Due To Inaccurate Readings At High LevelsCategory: Diabetes | Leave a Comment |
LifeScan, Inc. is conducting a voluntary recall in the United States of eight lots of OneTouch® SureStep® Test Strips, used by people with diabetes to measure their blood glucose levels at home. The test strips are being recalled because they may provide falsely low glucose results when the glucose level is higher than 400 mg/dL…
|
12
Feb |
Analysis Shows Minorities Less Likely To Receive “Cornerstone” Diabetes TestCategory: Diabetes | Leave a Comment |
Ethnic and racial minorities bear a disproportionate share of America’s diabetes epidemic but are significantly less likely than whites to receive a commonly used test to monitor control of blood glucose, according to Washington State University researchers…
Scientists in Cambridge have shown that an ‘artificial pancreas’ can be used to regulate blood glucose in children with Type 1 diabetes. A trial found that combining a real-time sensor measuring glucose levels with a pump that delivers insulin can boost overnight blood glucose control…
|
6
Feb |
Early Artificial Pancreas Trials Show Benefits For Kids, Teenagers With Diabetes While Sleeping OvernightCategory: Diabetes | Leave a Comment |
In a landmark study in children and teenagers with type 1 diabetes, JDRF-funded researchers at the University of Cambridge showed that using a first-generation artificial pancreas system overnight can lower the risk of low blood sugar emergencies while sleeping, and at the same time improve diabetes control…
|
3
Feb |
American Association Of Clinical Endocrinologists Approves New Diagnosis For DiabetesCategory: Diabetes | Leave a Comment |
The American Association of Clinical Endocrinologists (AACE) has approved the use of A1c as an additional diagnostic criterion for type 2 diabetes. An A1c of 6.5 or greater is now considered an alternate criterion for the diagnosis of type 2 diabetes. The decision was announced in a position statement entitled “The AACE/ACE Statement on the Use of A1c for the Diagnosis of Diabetes…
|
15
Jan |
ARKRAY, Inc. Launches The Assure(R) Platinum Auto Code Blood Glucose Monitoring SystemCategory: Diabetes | Leave a Comment |
ARKRAY, Inc., the world’s 5th largest manufacturer of diabetes self-monitoring systems, has officially launched the new Assure Platinum Blood Glucose Monitoring System. The Assure Platinum is now available for order and ready to ship in the U.S. market. The Assure Platinum Blood Glucose Monitoring System received 510(k) clearance from the FDA in December of 2009…
|
14
Jan |
Medical Care Technologies Inc. Commences Trials For Continuous Glucose Monitoring As Add-OnCategory: Diabetes | Leave a Comment |
Medical Care Technologies Inc. (OTCBB: MDCE) today announced that it has commenced trials to include Continuous Glucose Monitoring (CGM) to its current Tele-Health™ Suite. Management believes that by adding this function to its Tele-Health™ technology, users will be able to monitor and better control their diabetes while reducing costs…
|
14
Jan |
JDRF Forms Partnership With Animas To Develop First-Generation Automated System For Managing Type 1 DiabetesCategory: Diabetes | Leave a Comment |
The Juvenile Diabetes Research Foundation announced an innovative partnership with Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease — the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas, a fully automated sys…
|
12
Jan |
Echo Therapeutics Announces Major Milestone: The Completion Of Product Development Work Of Its Revolutionary, Patented Prelude(TM) SkinPrep SystemCategory: Diabetes | Leave a Comment |
Echo Therapeutics, Inc…